Phase II Study of Izalontamab Brengitecan (iza-bren) Combined with Toripalimab in Patients with Recurrent or Metastatic (R/M) Nasopharyngeal Cancer (NPC) (ESMO Asia 2026) - Oct 1, 2026 - Abstract #243RO; Pres time: Dec 6, 2026; 11:15 AM - 11:20 AM; Location: Hall 407; No abstract available
Clinical • Metastases • P2 data • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Solid Tumor
|